Latham & Watkins Advises Jade Biosciences on Public Offering of Common Stock

Jade Biosciences, Inc. (Jade) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, has announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of US$15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be US$150 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 5, 2026. In addition, Jade has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the public offering are being sold by Jade.

Latham & Watkins LLP represents Jade Biosciences in the offering with a corporate team led by partners Cheston Larson and Matt Bush, and counsel Anthony Gostanian, with associates Nadia Patiño, Shelby Harrison, and Katie Raya.